Interim results of PROVE 3: A randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon-alfa-2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy

Authors
Category Primary study
JournalHepatology International
Year 2009
This article has no abstract
Epistemonikos ID: 33f5a232f423478f7a57593f0f0a27cfa4dcf7ad
First added on: Feb 28, 2025